We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Roche Expands Into Cell Therapy With Adaptimmune Deal Worth Up to $3 Billion
Roche Expands Into Cell Therapy With Adaptimmune Deal Worth Up to $3 Billion
Roche has partnered with UK-based Adaptimmune Therapeutics to develop “off-the-shelf” T-cell therapies for up to five cancer targets in a deal valued at $150 million upfront but potentially worth up to $3 billion to the UK company.